References
- Lee HG, Choi HY, Bae JS. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney Int. 2014;86:1079–1081.
- Kali A, Shetty KS. Endocan: A novel circulating proteoglycan. Indian J Pharmacol. 2014;46:579–583.
- Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86:1213–1220.
- Celık T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. Blood Press. 2015;24:55–60.
- Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19:124–127.
- Arman Y, Akpinar TS, Kose M, et al. Effect of glycemic regulation on endocan levels in patients with diabetes: A preliminary study. Angiology. 2016;67:239–244.
- American Diabetes A. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S14–S80.
- Levey AS, Stevens LA, Schmid CH, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
- Wakelin SJ, Marson L, Howie SE, Garden J, Lamb JR, Forsythe JL. The role of vascular endothelial growth factor in the kidney in health and disease. Nephron Physiol. 2004;98:73–79.
- Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009;58:1471–1478.
- Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 2015;6:3–15.
- Georgalas I, Papaconstantinou D, Papadopoulos K, Pagoulatos D, Karagiannis D, Koutsandrea C. Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease – a possible side effect? Curr Drug Saf. 2014;9:156–158.
- Yanagawa T, Araki A, Sasamoto K, Shirabe S, Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metab Clin Exp. 2004;53:353–357.
- Koroshi A. Microalbuminuria, is it so important? Hippokratia. 2007;11:105–107.